40SD02

Drug Profile

40SD02

Latest Information Update: 04 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomedical Frontiers
  • Class
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Iron overload

Highest Development Phases

  • Discontinued Iron overload

Most Recent Events

  • 19 Dec 2003 Data presented at the 45th Annual Meeting of the American Society of Hematology (ASH-2003)have been added to the Haematological disorders therapeutic trials section
  • 28 Mar 2001 Phase-II clinical trials for Iron overload in USA (Injection)
  • 21 Dec 1998 40SD02 has received Orphan Drug Status for Iron overload in the USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top